Bernadette Connaughton insider trades

Open-market stock purchases and sales by Bernadette Connaughton, Director at Halozyme Therapeutics, Inc, from SEC Form 4 filings since Sep 7, 2018.

Recent trades

DateStockTradeValue
Aug 10, 2026HALO Halozyme Therapeutics, IncSold$167K
Jul 1, 2026HALO Halozyme Therapeutics, IncSold$76.4K
Jul 1, 2026HALO Halozyme Therapeutics, IncSold$48.3K
Jun 17, 2026EDIT Editas Medicine, IncBought (not open market)—
Jun 1, 2026HALO Halozyme Therapeutics, IncSold$108K
May 5, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
May 5, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
May 5, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
May 1, 2026HALO Halozyme Therapeutics, IncSold$103K
Jan 5, 2026HALO Halozyme Therapeutics, IncSold$141K
Dec 1, 2025HALO Halozyme Therapeutics, IncSold$59.4K
Nov 10, 2025HALO Halozyme Therapeutics, IncSold$137K

Companies traded

  • HALO Halozyme Therapeutics, Inc: 13 sales, last Aug 10, 2026
  • EDIT Editas Medicine, Inc: other filings, last Jun 17, 2026
  • SYNH Syneos Health, Inc: other filings, last Sep 28, 2023

Get free alerts when Bernadette Connaughton files a new trade →